TMCI May 2024 12.500 put
| Previous close | 2.0500 |
| Open | 2.0500 |
| Bid | 1.7000 |
| Ask | 2.6500 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 2.0500 - 2.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireTreace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour
Partnership to help pickleball players of all levels with bunions and related midfoot deformities to “get back on their feet” and out on the courtDALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The Professional Pickleball Association (PPA) Tour and Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedur
GlobeNewswireTreace to Present at Bank of America Health Care Conference
Wednesday, May 15, 2024, at 2:20 pm Pacific TimePONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fires
GlobeNewswireTreace Announces First Annual National Bunion Day
Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone DeformityPONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Pro
